Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Anna Berglöf"'
Autor:
Tom A. Mulder, Lucía Peña-Pérez, Anna Berglöf, Stephan Meinke, H. Yesid Estupiñán, Kia Heimersson, Rula Zain, Robert Månsson, C. I. Edvard Smith, Marzia Palma
Publikováno v:
HemaSphere, Vol 5, Iss 5, p e564 (2021)
Ibrutinib is a covalently binding inhibitor of the B-cell receptor signaling-mediator Bruton’s tyrosine kinase (BTK) with great efficacy in chronic lymphocytic leukemia (CLL). Common side effects like atrial fibrillation (AF), bleeding and infectio
Externí odkaz:
https://doaj.org/article/7612645b2ec14e5e86e2bbac72791afb
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK inhibitors (BTKis) in the clinic has increased considerably and c
Externí odkaz:
https://doaj.org/article/9f20a6c02d114dc6a85ef7b4ff3573dc
Publikováno v:
Frontiers in Cell and Developmental Biology
The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK inhibitors (BTKis) in the clinic has increased considerably and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::07f592f8ff033067dfa9dccbf49fd888
https://pubmed.ncbi.nlm.nih.gov/33777941
https://pubmed.ncbi.nlm.nih.gov/33777941
Autor:
H Yesid, Estupiñán, Qing, Wang, Anna, Berglöf, Gerard C P, Schaafsma, Yuye, Shi, Litao, Zhou, Dara K, Mohammad, Liang, Yu, Mauno, Vihinen, Rula, Zain, C I Edvard, Smith
Publikováno v:
Leukemia
Irreversible inhibitors of Bruton tyrosine kinase (BTK), pioneered by ibrutinib, have become breakthrough drugs in the treatment of leukemias and lymphomas. Resistance variants (mutations) occur, but in contrast to those identified for many other tyr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::91086abe031b25b831533c8a884f161c
https://pubmed.ncbi.nlm.nih.gov/33526860
https://pubmed.ncbi.nlm.nih.gov/33526860
Autor:
Ayla De Paepe, C. I. Edvard Smith, Jeanette Lundin, Masood Kamali-Moghaddam, Stephan Meinke, Anders Österborg, Aleksandra Krstic, Eva Kimby, K. Emelie M. Blomberg, Qing Wang, Georg Jaremko, Petter Höglund, Anna Berglöf, Marzia Palma, Lucia Peña Perez, Qiujin Shen, Robert Månsson
Publikováno v:
British Journal of Haematology. 183:212-224
In chronic lymphocytic leukaemia (CLL) patients, treatment with the Bruton tyrosine kinase inhibitor ibrutinib induces a rapid shift of tumour cells from lymph nodes (LN) to peripheral blood (PB). Here, we characterized in depth the dynamics of ibrut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc5b40eef50a87c07d6e448786ff266e
https://doi.org/10.1111/bjh.15516
https://doi.org/10.1111/bjh.15516
Autor:
Rula Zain, C. I. Edvard Smith, H. Yesid Estupiñán, Marzia Palma, Tom A. Mulder, Stephan Meinke, Kia Heimersson, Robert Månsson, Lucía Peña-Pérez, Anna Berglöf
Publikováno v:
HemaSphere, Vol 5, Iss 5, p e564 (2021)
HemaSphere
HemaSphere
Supplemental Digital Content is available in the text.
Ibrutinib is a covalently binding inhibitor of the B-cell receptor signaling-mediator Bruton’s tyrosine kinase (BTK) with great efficacy in chronic lymphocytic leukemia (CLL). Common side
Ibrutinib is a covalently binding inhibitor of the B-cell receptor signaling-mediator Bruton’s tyrosine kinase (BTK) with great efficacy in chronic lymphocytic leukemia (CLL). Common side
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::613abcdd4b8c9a435c2d94f8d481a7a4
https://doi.org/10.1097/hs9.0000000000000564
https://doi.org/10.1097/hs9.0000000000000564
Autor:
K E M Blomberg, A. Hamasy, C. I. E. Smith, Anna Berglöf, Mauno Vihinen, Liang Yu, Dara K. Mohammad, Qing Wang
Publikováno v:
Leukemia
Irreversible Bruton tyrosine kinase (BTK) inhibitors, ibrutinib and acalabrutinib have demonstrated remarkable clinical responses in multiple B-cell malignancies. Acquired resistance has been identified in a sub-population of patients in which mutati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18262eda30c93529b5d145efe4cd1c8b
https://doi.org/10.1038/leu.2016.153
https://doi.org/10.1038/leu.2016.153
Autor:
Eva Kimby, Marzia Palma, A. Hamasy, Anders Österborg, C. I. E. Smith, Stephan Meinke, Robert Månsson, Anna Berglöf, Aleksandra Krstic
Publikováno v:
Scandinavian Journal of Immunology
Ibrutinib (Imbruvica™) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK). Over the last few years, ibrutinib has developed from a promising drug candidate to being approved by FDA for the treatment of three B cell malignancies,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c54282aacd92a42dd0fecb7311f59701
https://doi.org/10.1111/sji.12333
https://doi.org/10.1111/sji.12333
Autor:
Dara K. Mohammad, Hernando Yesid Estupiñan Velasquez, Anna Berglöf, Qing Wang, Edvard C.I. Smith, Rula Zain, Yuye Shi, Mauno Vihinen
Publikováno v:
Blood. 134:5759-5759
Resistance to the irreversible Bruton´s tyrosine kinase (BTK) inhibitors is the main cause of disease progression in patients with Chronic Lymphocytic Leukemia (Quinquenel et. al. Blood 2019). Cysteine to serine substitution at the position 481 in B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e7a63f42611a97deaafc0080e5c3388
https://doi.org/10.1182/blood-2019-123398
https://doi.org/10.1182/blood-2019-123398
Autor:
K. Emelie M. Blomberg, Anna Berglöf, Janne J. Turunen, Burcu Bestas, C. I. Edvard Smith, Olof Gissberg
Publikováno v:
Expert Review of Clinical Immunology. 9:1205-1221
Agammaglobulinemias are primary (inherited) immunodeficiencies characterized by the lack of functional B-cells and antibodies, and are caused by mutations in genes encoding components of the pre-B-cell or B-cell receptor, or their signaling pathways.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50c60f17fe4077a1f22d51effd391264
https://doi.org/10.1586/1744666x.2013.850030
https://doi.org/10.1586/1744666x.2013.850030